<b>Four-Month High-Dose Rifampicin Regimens for Pulmonary Tuberculosis (Rifashort)</b>
dataset
posted on 2024-11-25, 12:25 authored by Amina JindaniAmina Jindani, Daniel Atwine, Daniel Grint, Boubacar Bah, Jack AdamsJack Adams, Eduardo Rómulo Ticona, Bhabana Shrestha<p dir="ltr"><b>Four-month regimens including high-dose rifampicin were associated with few adverse events but did not meet noninferiority criteria.</b></p>
Funding
MRC/Wellcome Trust/DFID Joint Global Health Trials Scheme. This work was also funded by the Aga Khan Foundation.
History
Related Materials
- 1.
Research Institute
- Infection and Immunity
